Top Markets
Coin of the day
Acticor Biotech SAS Acticor Biotech SAS

Acticor Biotech SAS

ALACT
Pozycja w akcjach #37014
Acticor Biotech SAS is a clinical-stage biotechnology firm focused on creating... Acticor Biotech SAS is a clinical-stage biotechnology firm focused on creating therapies for the acute phase of thrombotic conditions. The company's lead compound, glenzocimab, is a humanized monoclonal antibody fragment specifically designed to target a particular platelet glycoprotein. Currently, Acticor Biotech is advancing two clinical programs, both in Phase II/III, for the registration of treatments for ischemic stroke. Additionally, it is conducting two other Phase II trials concerning significant cardiovascular emergencies, with anticipated clinical data expected from both its ischemic stroke research and studies related to COVID-19 respiratory distress syndrome. Established in 2013, the company operates from its headquarters in Paris, France.
Cena akcji
$0.25974701
Ostatnia synchronizacja: 2025-01-06
Kapitalizacja rynkowa
$2.04M
Zmiana (1 dzień)
0.74%
Zmiana (1 rok)
0.00%
Kraj
FR
Handel Acticor Biotech SAS (ALACT)

Kategoria

Zyski dla Acticor Biotech SAS (ALACT)
Zyski w Jun 2024 TTM: $-12.93M
Według najnowszych raportów finansowych Acticor Biotech SAS, obecny zysk firmy wynosi $-12.93M. W roku 2022 firma osiągnęła zysk w wysokości $-19.33M, spadek w porównaniu do zysku z roku 2021, który wynosił $-16.54M. Wyświetlany zysk to zysk przed odsetkami i podatkami, czyli EBIT.
Historia zysków firmy Acticor Biotech SAS od 2010 do 2026
Zyski na koniec każdego roku
Rok Zyski Zmień
2026 (TTM) $-12.93M -43.60%
2023 $-22.92M 18.60%
2022 $-19.33M 16.85%
2021 $-16.54M 50.20%
2020 $-11.01M 86.82%
2019 $-5.89M -14.36%
2018 $-6.88M -41.98%
2017 $-11.86M 2,061.40%
2016 $-548.85K -76.37%
2015 $-2.32M 97.57%
2014 $-1.18M -131.38%
2013 $3.75M -11.81%
2012 $4.25M 30.59%
2011 $3.25M 275.68%
2010 $865.72K 0.00%
Zyski podobnych firm lub konkurentów
Firma Zyski Różnica w zyskach Kraj
$5.27B -40,906.21%
US
$1.95B -15,190.08%
NL
$-4.02B 30,968.98%
AU
$-3.09B 23,780.79%
US
- -
CH